Kaitlyn D’Onofrio

DocwireNews

<p>According to findings from the Phase III THEMIS trial, patients with type 2 diabetes who took ticagrelor in conjunction with aspirin significantly reduced their risk of adverse cardiovascular outcomes compared to patients taking aspirin alone.<p>THEMIS measured the efficacy of AstraZeneca&rsquo;s Brilinta.</p><h2><strong>THEMIS</strong></h2><p>The randomized, double-blinded <a href="https://ichgcp.net/clinical-trials-registry/NCT01991795">THEMIS</a> (Effect of Ticagrelor on Health Outcomes in DiabEtes Mellitus Patients Intervention Study) trial, sponsored by AstraZeneca, included over 19,000 patients with coronary artery disease and type 2 diabetes who had no history of myocardial infarction or stroke. The trial began in 2013. The primary outcome was the first occurrence of any event from the composite of cardiovascular death, myocardial infarction, or stroke. Secondary outcomes included prevention of cardiovascular death, myocardial infarction, ischemic stroke, and all-cause death.</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">AstraZeneca: Positive results from Brilinta trial <a href="https://t.co/Oqj2pDWepI">https://t.co/Oqj2pDWepI</a></p>
<p>&mdash; MarketWatch (@MarketWatch) <a href="https://twitter.com/MarketWatch/status/1099954282936369152?ref_src=twsrc%5Etfw">February 25, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><p>According to a <a href="https://www.astrazeneca.com/media-centre/press-releases/2019/brilintas-phase-iii-themis-trial-met-primary-endpoint-in-patients-with-established-coronary-artery-disease-and-type-2-diabetes-25022019.html">press release</a>, the trial&rsquo;s preliminary safety results were consistent with Brilinta&rsquo;s safety profile. The full data has yet to be released but will be shared at an upcoming medical meeting.</p><p>&ldquo;The THEMIS trial is the largest [randomized] trial of patients with type-2 diabetes performed to date and was designed to evaluate whether more-intense antiplatelet therapy is a promising approach,&rdquo; said Deepak L. Bhatt, MD, MPH, THEMIS co-chair and executive director of Interventional Cardiovascular Programs at Brigham and Women&rsquo;s Hospital and a Professor at Harvard Medical School. &ldquo;The results could help us refine our understanding of the role of dual antiplatelet therapy in patients across the atherothrombotic spectrum.&rdquo;</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">AstraZeneca has chalked up another clinical trial win for its antiplatelet drug Brilinta, showing that it can reduce cardiovascular events in diabetics with coronary artery disease (CAD). <a href="https://t.co/irTFdFBMVS">https://t.co/irTFdFBMVS</a> <a href="https://twitter.com/hashtag/pharma?src=hash&amp;ref_src=twsrc%5Etfw">#pharma</a></p>
<p>&mdash; Pharmaceutical Market Europe (@PMLiVEcom) <a href="https://twitter.com/PMLiVEcom/status/1099996404221661185?ref_src=twsrc%5Etfw">February 25, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><p>&ldquo;Patients who have both stable coronary artery disease and diabetes are a sizeable group which remains at particularly high risk of major adverse cardiac events,&rdquo; said Gabriel Steg, MD, THEMIS co-chair and professor at Universit&eacute; Paris-Diderot, Paris as well as at the National Heart and Lung Institute, Imperial College, London. &ldquo;The optimal long-term antiplatelet therapy in that group is not fully established. We look forward to presenting the full results from the THEMIS trial later this year.&rdquo;</p><p>https://twitter.com/PrescriptionBio/status/1100003865556971521</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">AstraZeneca's clot-fighter Brilinta shows promise in diabetics with heart disease in big study <a href="https://t.co/hqi5RfoBwt">https://t.co/hqi5RfoBwt</a> &gt;&gt;&gt; <a href="https://t.co/HTA6IsoHwv">https://t.co/HTA6IsoHwv</a> <a href="https://twitter.com/hashtag/strategy?src=hash&amp;ref_src=twsrc%5Etfw">#strategy</a> <a href="https://twitter.com/hashtag/competitiveintelligence?src=hash&amp;ref_src=twsrc%5Etfw">#competitiveintelligence</a> <a href="https://twitter.com/hashtag/marketing?src=hash&amp;ref_src=twsrc%5Etfw">#marketing</a> <a href="https://twitter.com/hashtag/pharma?src=hash&amp;ref_src=twsrc%5Etfw">#pharma</a> <a href="https://twitter.com/hashtag/CI?src=hash&amp;ref_src=twsrc%5Etfw">#CI</a> <a href="https://twitter.com/hashtag/biotech?src=hash&amp;ref_src=twsrc%5Etfw">#biotech</a> <a href="https://twitter.com/hashtag/pharmaceutical?src=hash&amp;ref_src=twsrc%5Etfw">#pharmaceutical</a> <a href="https://twitter.com/hashtag/healthcare?src=hash&amp;ref_src=twsrc%5Etfw">#healthcare</a> <a href="https://t.co/H4K0JvV5T4">pic.twitter.com/H4K0JvV5T4</a></p>
<p>&mdash; Dr Timos Papagatsias (@_timos_) <a href="https://twitter.com/_timos_/status/1100056589807960064?ref_src=twsrc%5Etfw">February 25, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><p>https://twitter.com/GeorgeMentz/status/1100093084543549441</p></p>


Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Ticagrelor Reduces Cardiovascular Events in Type 2 Diabetes Patients

Cardiology

According to findings from the Phase III THEMIS trial, patients with type 2 diabetes who took ticagrelor in conjunction with aspirin significantly reduced their risk of ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe